“I would like to thank the Spectral board and my colleagues for the opportunity to serve as the Company’s CFO,” said
“We would like to thank Blair for his leadership and many valuable contributions to our recent successes and wish him the very best in his future endeavors,’ said
Spectral will conduct a formal search process in due course to choose a new Chief Financial Officer. In the interim,
Amended Advance Notice By-Law
Spectral also announced that its Board of Directors has amended and updated its advance notice by-law that establishes a framework for the advance notice of nominations of directors of Spectral by shareholders. Among other things, the advance notice by-law establishes deadlines by which shareholders must notify Spectral of nominations of directors prior to a meeting of Spectral shareholders and sets forth the information that must be included with such a nomination and the method by which a nomination must be delivered to Spectral.
The amended and updated advance notice by-law is effective immediately and will be placed before shareholders for approval and ratification at the next annual and special meeting of shareholders expected to be held in the second quarter of 2024.
The full text of the Advance Notice By-law is available under the Company's profile at www.sedarplus.ca.
About Spectral
Spectral is a Phase 3 company seeking
PMX is approved for therapeutic use in
Spectral is listed on the
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company’s ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter’s commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
Capital Markets & Investor Relations | US Investor Relations | CEO |
416-962-3300 | 212-671-1020 | 416-626-3233 |
am@spinnakercmi.com | edt@crescendo-ir.com | cseto@spectraldx.com |
Source:
2023 GlobeNewswire, Inc., source